Spreely +
  • Home
  • Social
  • News
  • TV
  • Radio
  • Podcasts
  • Marketplace
  • Advertise
  • Get the App
  • Home
  • Social
  • News
  • TV
  • Radio
  • Podcasts
  • Marketplace
  • Advertise
  • Get the App

Spreely News

  • Politics
  • Business
  • Finance
  • Technology
  • Health
  • Sports
  • Politics
  • Business
  • Finance
  • Technology
  • Health
  • Sports
Home»Spreely News

Experimental Pill Shrinks Pancreatic Tumors In Most Patients

Ella FordBy Ella FordNovember 20, 2026 Spreely News No Comments4 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email

Early results from a new pancreatic cancer study are drawing attention because they show something doctors rarely get to say about this disease: tumors shrank, growth stalled, and a small share of patients saw scans come back clear. The treatment pairs a daily experimental pill with standard chemotherapy, and the early numbers point to a real opening in a cancer that has long been tough to move against.

The trial was presented at a major cancer conference in Barcelona and looked at 61 patients with metastatic pancreatic cancer who had not yet been treated for their advanced disease. Everyone in the study received daraxonrasib, the oral drug being tested, along with gemcitabine and nab-paclitaxel, two commonly used chemotherapy medicines.

That setup matters because pancreatic cancer often stays hidden until it has already spread. Once it reaches that stage, chemotherapy alone has a limited track record, with tumors shrinking in only a portion of patients and the disease often bouncing back within months.

Against that backdrop, the new results stand out. Tumors shrank in 60.7% of patients, and in 8.2% of cases the cancer disappeared on scans altogether. Even more striking, the combination kept the disease from progressing in 90.2% of participants.

The timing also looks encouraging. Patients went a median of 12.8 months before the cancer worsened, which is notably longer than the usual window seen with standard treatment alone. At the one-year mark, 76.6% of patients were still alive, another sign that this approach may be changing the math for at least some people.

Researchers say the science behind the drug is part of what makes the result so interesting. More than 90% of pancreatic cancers are driven by RAS, a faulty gene that keeps telling tumors to grow, and daraxonrasib is designed to shut down that signal.

That is a big deal because RAS has long been treated like a hard wall in cancer research. Scientists spent years chasing ways to block it, and this kind of response suggests that wall may not be as solid as once believed.

Dr. Wungki Park, the study lead and a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said the early findings showed not just shrinkage but durable control of the disease. The message from the data is hard to miss, especially in a cancer where durable wins are rare.

See also  Navarro Supreme Court Fight Could Raise Subpoena Conviction Bar

Safety is always the next question, and the side effects so far were in familiar territory for patients receiving chemotherapy. Rash, diarrhea, fatigue, and low blood cell counts were reported, but most were manageable with standard care.

Only 5% of patients stopped treatment because of side effects tied to daraxonrasib. That kind of tolerability matters, because even a promising cancer drug has to stay on board long enough to do its job.

Still, the numbers come with an important caveat. This was an early-phase study, it had no comparison group taking standard chemotherapy alone, and every patient got the experimental combination. That means the results are exciting, but they are not the final word.

The research also applies only to metastatic pancreatic cancer for now, even though RAS mutations show up in other cancers such as some lung, colorectal, and gynecological tumors. Separate trials will be needed before anyone can know whether the same strategy works just as well elsewhere.

A larger randomized Phase 3 trial called RASolute-303 is already underway to put the approach to a tougher test. It will compare daraxonrasib by itself and in combination with chemotherapy against standard chemotherapy alone, which should give doctors a much clearer picture of whether this early spark turns into a lasting edge.

Health
Ella Ford

Keep Reading

Federal Report Finds AI Platforms Generated Terror Plans

Uber Launches Parking Reservations, Adds Robotaxi Plans

2026 MLS Cup Playoffs First Round Predictions: Will Messi, Inter Miami Advance?

Way-Too-Early Predictions For The UEFA Nations League Quarterfinals

College Basketball Catchup: A Tournament Record, Oregon's Star, A New-Look Maine

4 TV Brands Rated Higher Than Sony For TVs

Add A Comment
Leave A Reply Cancel Reply

All Rights Reserved

Policies

  • Politics
  • Business
  • Finance
  • Technology
  • Health
  • Sports
  • Politics
  • Business
  • Finance
  • Technology
  • Health
  • Sports

Subscribe to our newsletter

Facebook X (Twitter) Instagram Pinterest
© 2026 Spreely Media. Turbocharged by AdRevv By Spreely.

Type above and press Enter to search. Press Esc to cancel.